Prices are closing data as of 2026-11-04, not real-time quotes. HK P/E and P/B multiples come from Eastmoney HK key statistics. Metric definitions: P/E, P/B, ROE.
Want the full AI research report for CHINARES PHARMA?
This free page compiles public filings, financial ratios and risk screening. Generate a full research report to add business moat & competition, valuation scenarios, catalysts and bull/bear cases right at this URL.
New users who sign up free and verify their email receive 2 free credits for research reports or professional valuation.
10-Year FinancialsFY2016–2025
Financial statements are reported in CNY, while share price and market cap are quoted in HKD.
Key Multi-Year Facts
- Revenue moved from CN¥156.7B in FY2016 to CN¥269.6B in FY2025 (9-year CAGR +6.2%).
- Profitable in every fiscal year across 2016–2025.
Latest 5 Fiscal Years
| Fiscal Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue (CNY B) | 237 | 218 | 245 | 258 | 270 |
| YoY | 18.2% | -7.9% | 12.2% | 5.3% | 4.6% |
| Net Income (CNY B) | 3.77 | 3.50 | 3.85 | 3.35 | 4.05 |
| YoY | 14.3% | -7.1% | 10.1% | -13.1% | 20.7% |
| Operating Cash Flow (CNY B) | 10.5 | 10.8 | 15.5 | 17.5 | 20.5 |
| ROE | 8.6% | 8.2% | 8.6% | 7.1% | 8.1% |
| Gross Margin | 14.9% | 15.4% | 15.7% | 15.8% | 16.5% |
| Net Margin | 1.6% | 1.6% | 1.6% | 1.3% | 1.5% |
| Debt-to-Assets | 61.8% | 62.6% | 62.3% | 61.9% | 58.9% |
Show all 10 fiscal years
| Fiscal Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (CNY B) | 157 | 173 | 190 | 204 | 200 | 237 | 218 | 245 | 258 | 270 |
| YoY | — | 10.1% | 9.9% | 7.8% | -2.0% | 18.2% | -7.9% | 12.2% | 5.3% | 4.6% |
| Net Income (CNY B) | 2.82 | 3.48 | 3.98 | 3.29 | 3.30 | 3.77 | 3.50 | 3.85 | 3.35 | 4.05 |
| YoY | — | 23.5% | 14.2% | -17.4% | 0.3% | 14.3% | -7.1% | 10.1% | -13.1% | 20.7% |
| Operating Cash Flow (CNY B) | 3.69 | 4.06 | 7.23 | 7.29 | 6.91 | 10.5 | 10.8 | 15.5 | 17.5 | 20.5 |
| ROE | 7.5% | 8.8% | 9.8% | 8.2% | 7.6% | 8.6% | 8.2% | 8.6% | 7.1% | 8.1% |
| Gross Margin | 15.4% | 16.4% | 18.4% | 16.6% | 16.1% | 14.9% | 15.4% | 15.7% | 15.8% | 16.5% |
| Net Margin | 1.8% | 2.0% | 2.1% | 1.6% | 1.6% | 1.6% | 1.6% | 1.6% | 1.3% | 1.5% |
| Debt-to-Assets | 59.5% | 60.7% | 65.7% | 63.4% | 61.8% | 61.8% | 62.6% | 62.3% | 61.9% | 58.9% |
Fiscal years follow the period-end calendar year (hover headers for period-end dates). ROE uses average beginning/ending equity. Source: HKEX / Eastmoney financial statements, compiled mechanically without AI. Official filings
Risk ChecklistAs of 2026-11-05
Rules-based screening using HK financial statements and HKEX announcement categories (no AI opinions).
Items Flagged for Review
- Alert
-
Alert
Short-Term Debt CoverageSolvency
Cash CN¥15.62B, short-term debt CN¥52.93B (0.30x)
Interim (2026-06-30) · What is this?
-
Watch
Profit WarningMaterial Events
An "Alert" or "Watch" item flags a number that merits verification in primary filings, not a sell signal.
Dividends
Trailing 12-month dividend: HK$0.240 per share, or 5.11% yield at closing price; last full fiscal year: HK$0.218 (payout ratio 31.7%).
Figures are gross HKD per share before applicable withholding or Stock Connect dividend taxes.
More data: All research reports · Sector leaders · Market hours & holidays.
Compiled mechanically from public filings and market quotes (data as of 2026-11-05). For informational purposes only, not investment advice.